FDA grants ODD to Keros KER-065 for treatment of Duchenne muscular dystrophy
KER-065 is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB
KER-065 is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
The acquired ANDAs represent a market opportunity of about US$ 38 million in the USA
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Marksans Pharma gets USFDA nod for acid reflux drug
FDA grants accelerated approval to zongertinib for HER2 TKD-Mutated Non-Squamous NSCLC
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Norepinephrine Bitartratein 5% Dextrose of Baxter Healthcare Corp
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), KENGREAL of Chiesi USA
Subscribe To Our Newsletter & Stay Updated